跳至主要内容
临床试验/NCT02018939
NCT02018939已完成3 期

Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.

Medical University of Vienna2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2010年3月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
24
试验地点
2
主要终点
Influence of organ replacement therapy on area under curve of doripenem serum concentration

研究概览

简要总结

The study is conducted to investigate the pharmacokinetics of Doripenem during CVVHDF (Continuous venovenous hemodiafiltration), MARS (Molecular Adsorbent Recirculating System) and intermittent hemodialysis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Suspected or proven bacterial infection requiring parenteral antibiotic therapy.
  • Organ replacement therapy (MARS, CVVHDF or HD)

排除标准

  • Known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents.
  • An expected survival of less than two days.
  • Known pregnancy
  • Coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study
  • Doripenem as monotherapy for resistent species or fungal infections.
  • Other reasons opposing the study participation on the discretion of the investigators.

结局指标

主要结局

Influence of organ replacement therapy on area under curve of doripenem serum concentration

时间窗: day 15

Pharmacokinetic samples are drawn from each patient during the trial. Analysis by HPLC will be conducted after the end of the trial.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Florian Thalhammer

a.o.Univ.-Prof. Dr.

Medical University of Vienna

研究点 (2)

Loading locations...

相似试验